Lakewood-Amedex outlines Nu-3 clinical progress after Nasdaq listing Sep 21, 2026 08:03AM
Lakewood-Amedex gets IRB approval for diabetic foot ulcer trial Sep 18, 2026 04:03PM
Lakewood-Amedex shares resistance data for antibiotic candidate Nu-3 Jul 22, 2026 08:03AM
Lakewood-Amedex backs PASTEUR Act, plans Phase 2 trial for Nu-3 Jul 7, 2026 08:03AM
Lakewood-Amedex receives Australian patent for antimicrobial compounds Jun 22, 2026 08:04AM


May 27, 2026 08:03AM Lakewood-Amedex secures patents in Australia and New Zealand for Nu-3
May 18, 2026 08:02AM Lakewood-Amedex completes manufacturing steps for Nu-3 diabetes drug trial
May 1, 2026 08:05AM Lakewood-Amedex reports low resistance development in antimicrobial tests
Apr 23, 2026 10:44AM Lakewood-Amedex begins trading on NASDAQ under ticker LABT